Fate Therapeutics (FATE) Assets (2012 - 2026)

Fate Therapeutics' Assets history runs 15 years deep, the most recent figure standing at $284.9 million for Q1 2026.

• Quarterly Assets fell 28.53% year-over-year to $284.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284.9 million (down 28.53% YoY) and the FY2025 annual result came in at $318.9 million, down 27.63% from the prior year.
• Assets was $284.9 million for Q1 2026 at Fate Therapeutics, down from $318.9 million in the prior quarter.
• Across five years, Assets topped out at $858.4 million in Q1 2022 and bottomed at $284.9 million in Q1 2026.
• A 5-year average of $537.5 million and a median of $528.8 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2024 — Assets retreated 8.98% — and 2025, when it slumped 30.57%.
• Fate Therapeutics' Assets stood at $705.6 million in 2022, then retreated by 28.25% to $506.2 million in 2023, then retreated by 12.94% to $440.7 million in 2024, then dropped by 27.63% to $318.9 million in 2025, then retreated by 10.67% to $284.9 million in 2026.
• Business Quant data shows FATE's Assets at $284.9 million in Q1 2026, $318.9 million in Q4 2025, and $343.7 million in Q3 2025.